Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
PharmaVigilant
PharmaVigilant Launches Electronic Capture Database for Phase 1/2 Oncology Trial in 4 Weeks for Threshold Pharmaceuticals
November 25th, 2008
PharmaVigilant announced they launched an electronic data capture database for a Phase 1/2 oncology study in 4 weeks for Threshold Pharmaceuticals. The clinical trial design includes three separate treatment arms examining escalating doses of TH-302, Threshold's proprietary Hypoxia Activated Prodrug in combination with the following chemotherapeutic agents: Gemcitabine, Docetaxel or Pemetrexed. The Phase 1/2 study database design required the creation of over 50 unique case report forms and six separate CRF books to accommodate the study population. The flexibility built into the database design of this oncology trial will enable Threshold to better manage enrollment and the data...
Source: Cancer Weekly (2008-11-25)
|
